TY - JOUR
T1 - Ocular complications following treatment in the Postnatal Growth and Retinopathy of Prematurity (G-ROP) Study
AU - G-ROP Study Group
AU - Morrison, David
AU - Shaffer, James
AU - Ying, Gui Shuang
AU - Binenbaum, Gil
AU - Binenbaum, Gil
AU - Tomlinson, Lauren A.
AU - Duros, Trang B.
AU - Ying, Gui shuang
AU - Maguire, Maureen G.
AU - Brightwell-Arnold, Mary
AU - Shaffer, James
AU - Blanco, Maria
AU - Brown, Trina
AU - Helker, Christopher P.
AU - Barry, Gerard P.
AU - Fisher, Marilyn
AU - Battaglia, Maria V.
AU - Drach, Alex M.
AU - Donohue, Pamela
AU - Repka, Michael X.
AU - Doherty, Megan
AU - Dow, Dorothy
AU - Shepard, Jennifer A.
AU - Reynolds, James D.
AU - Connelly, Erin
AU - Cheeseman, Edward
AU - Bradham, Carol
AU - McAlpine, Allison
AU - Sunthankar, Sudeep
AU - Shirer, Kinsey
AU - Abbasian, Javaneh
AU - Lim, Janet
AU - Yang, Michael
AU - Alfano, Elizabeth L.
AU - Cobb, Patricia
AU - Rogers, David
AU - Fellows, Rae R.
AU - Loh, Kaitlyn
AU - McGregor, Madeline A.
AU - Mustafa, Thabit
AU - Reem, Rachel E.
AU - Russell, Tess
AU - Stattler, Rebecca
AU - Oravec, Sara
AU - Young, David
AU - Siu, Andrea
AU - Kanemori, Michele
AU - Wang, Jingyun
AU - Haider, Kathryn
AU - Hynes, Elizabeth
N1 - Publisher Copyright:
© 2018 American Association for Pediatric Ophthalmology and Strabismus
PY - 2018/4
Y1 - 2018/4
N2 - Purpose: To determine the prevalence of treatment-related ocular complications and disease progression following treatment for retinopathy of prematurity (ROP). Methods: This was a retrospective cohort study of eyes treated for ROP at 29 North American neonatal intensive care units in the Postnatal Growth and ROP (G-ROP) Study. Data from the time of treatment through 15 months were abstracted from medical records by certified data collectors. Treatment-related complication (cataract, hyphema, glaucoma, corneal abrasion/opacity), and disease-progression (retinal fold, dragging, or stage 4 or 5 detachment) were calculated by treatment modality. Vitreous hemorrhage was classified separately, because it can relate to treatment or disease progression. Results: Of 7,483 infants included in the study, 1,004 eyes (512 infants) underwent ROP treatment: 970 eyes received laser as initial therapy; 34 eyes received intravitreal bevacizumab (IVB). Median follow-up after treatment was 18 weeks. Overall, one or more complications occurred in 2.6% (95% CI, 1.8%-3.8%) laser treated eyes and no (0%; 95% CI, 0.0%-10.1%) IVB eyes. Disease-progression occurred in 9.2% (95% CI, 7.6%-11.2%) laser treated eyes, no (0%; 95% CI, 0.0-12.9%) IVB-only eyes. Vitreous hemorrhage occurred in 5.4% (95% CI: 4.1% - 7.0%) laser treated eyes, no IVB-only eyes. Conclusions: Rates of complications are very low following ROP treatment with either laser or IVB. Of laser-treated eyes, 9% experienced disease progression despite treatment.
AB - Purpose: To determine the prevalence of treatment-related ocular complications and disease progression following treatment for retinopathy of prematurity (ROP). Methods: This was a retrospective cohort study of eyes treated for ROP at 29 North American neonatal intensive care units in the Postnatal Growth and ROP (G-ROP) Study. Data from the time of treatment through 15 months were abstracted from medical records by certified data collectors. Treatment-related complication (cataract, hyphema, glaucoma, corneal abrasion/opacity), and disease-progression (retinal fold, dragging, or stage 4 or 5 detachment) were calculated by treatment modality. Vitreous hemorrhage was classified separately, because it can relate to treatment or disease progression. Results: Of 7,483 infants included in the study, 1,004 eyes (512 infants) underwent ROP treatment: 970 eyes received laser as initial therapy; 34 eyes received intravitreal bevacizumab (IVB). Median follow-up after treatment was 18 weeks. Overall, one or more complications occurred in 2.6% (95% CI, 1.8%-3.8%) laser treated eyes and no (0%; 95% CI, 0.0%-10.1%) IVB eyes. Disease-progression occurred in 9.2% (95% CI, 7.6%-11.2%) laser treated eyes, no (0%; 95% CI, 0.0-12.9%) IVB-only eyes. Vitreous hemorrhage occurred in 5.4% (95% CI: 4.1% - 7.0%) laser treated eyes, no IVB-only eyes. Conclusions: Rates of complications are very low following ROP treatment with either laser or IVB. Of laser-treated eyes, 9% experienced disease progression despite treatment.
UR - http://www.scopus.com/inward/record.url?scp=85045760865&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85045760865&partnerID=8YFLogxK
U2 - 10.1016/j.jaapos.2017.12.005
DO - 10.1016/j.jaapos.2017.12.005
M3 - Article
C2 - 29548840
AN - SCOPUS:85045760865
SN - 1091-8531
VL - 22
SP - 128
EP - 133
JO - Journal of AAPOS
JF - Journal of AAPOS
IS - 2
ER -